Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
11.14
+0.48 (4.50%)
Dec 20, 2024, 4:00 PM EST - Market closed
Gyre Therapeutics Revenue
Gyre Therapeutics had revenue of $25.49M in the quarter ending September 30, 2024, a decrease of -13.10%. This brings the company's revenue in the last twelve months to $105.03M, down -9.04% year-over-year. In the year 2023, Gyre Therapeutics had annual revenue of $113.45M with 10.91% growth.
Revenue (ttm)
$105.03M
Revenue Growth
-9.04%
P/S Ratio
8.67
Revenue / Employee
$177,121
Employees
593
Market Cap
956.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
Dec 31, 2022 | 102.29M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGYRE News
- 5 weeks ago - Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - GlobeNewsWire
- 2 months ago - Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Gyre Therapeutics to Present at Sidoti Virtual Investor Conference - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology - GlobeNewsWire
- 7 months ago - Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire